Literature DB >> 32145404

Response of omalizumab in normocomplementemic urticarial vasculitis.

Yu-Di Chen1, Karoline Krause2, Ping Tu1, Zuo-Tao Zhao3, Marcus Maurer4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32145404     DOI: 10.1016/j.jaip.2020.02.024

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  2 in total

Review 1.  The Emerging Role of Mast Cells in Response to Fungal Infection.

Authors:  Miao Yu; Xiao-Ting Song; Bo Liu; Ting-Ting Luan; Shuang-Lu Liao; Zuo-Tao Zhao
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

2.  Real-World Experience on Omalizumab Treatment for Patients with Normocomplementemic Urticarial Vasculitis.

Authors:  Taoming Liu; Juan Bai; Shuni Ying; Sheng Li; Yunlei Pan; Deren Fang; Jianjun Qiao; Hong Fang
Journal:  J Asthma Allergy       Date:  2021-04-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.